Addex to Present at the 2025 Swiss Equities Baader Conference

Geneva, Switzerland, January 8, 2025 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that Dr Robert Lütjens, Head of Discovery - Biology, will present at the Swiss Equities Baader Conference being held in Bad Ragaz, Switzerland, January 08-10, 2025. In his presentation, Dr Lütjens will provide a corporate update and discuss recent advances from Addex' ...